Filing Details

Accession Number:
0001213900-24-004190
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-17 16:50:12
Reporting Period:
2024-01-12
Accepted Time:
2024-01-17 16:50:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
819050 Fresh Tracks Therapeutics Inc. FRTX Biological Products, (No Disgnostic Substances) (2836) 930948554
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
2003514 Exploration Capital, Llc 250 East 200 South, Floor 16
Salt Lake City UT 84111
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-12 10,958 $0.98 840,962 No 4 P Direct
Common Stock Acquisiton 2024-01-17 9,038 $0.99 850,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 47,000 Direct
Footnotes
  1. Exploration Capital, LLC ("X-Cap") is the investment manager of Exploration Capital Fund, LP (the "Partnership") and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership. Exploration Capital General Partner, LLC (the "GP") is the general partner of the Partnership and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership.
  2. Stephen L. Gustin is the Managing Partner of X-Cap and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership. Mr. Gustin disclaims beneficial ownership of the reported securities held by the Partnership except to the extent of his pecuniary interest.
  3. These shares are directly owned by Stephen L. Gustin.